GeneMatrix
GeneMatrix is a South Korea-based molecular diagnostics company that develops and sells the NeoPlex™ line of proprietary multiplex real-time PCR kits, serving clinical laboratories and hospitals globally across infectious disease, HPV, STI, TB, and respiratory testing, while also advancing a six-candidate vaccine pipeline.
- Company typePublic
- Founded2000
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What GeneMatrix does
GeneMatrix (Genematrix Inc.) is a South Korea-based molecular diagnostics company founded in 2000 and listed on KOSDAQ (ticker: 109820) since 2009. The company develops and sells the NeoPlex™ line of multiplex real-time PCR diagnostic kits built on its proprietary C-Tag™ technology, which enables simultaneous detection of up to 20 pathogen targets in a single tube. The product portfolio spans sexually transmitted infections (STI-7, STI-7 PLUS, STI-14), human papillomavirus (HPV29 and HPV HR), respiratory infections (RV-Panel A for 10 viruses, RV-Panel B for 9 viruses, RB-8 for 8 bacteria, FluCOVID, COVID-19 FAST), tuberculosis (TB/NTM-5), and gastrointestinal infections (GI-Virus 6). Beyond C-Tag™, the technology stack includes EnCleap™ primer technology for non-specific amplification suppression, TriO™ for high-sensitivity subtype detection, and RFMP™ MALDI-TOF genotyping.
GeneMatrix serves clinical laboratories, hospitals, and reference laboratories globally, with distribution concentrated in Asia (Korea), Europe (post-CE-IVDR certification), the Middle East (Dubai via Medlab), and North America (post-FDA EUA). Revenue is generated primarily through one-time sales of diagnostic kits in standardized formats (96 tests/kit, 50 tests/kit) via direct website inquiries and international exhibition channels; biochemical diagnostic reagents are sold through the wholly-owned HBI subsidiary (HiSens™ brand) acquired in 2011. The company also operates a vaccine development pipeline of six candidates (hepatitis A, Japanese encephalitis, herpes zoster, COVID-19, Zika, HPV therapeutic), leveraging the Chim-Ad chimeric adenovirus vector platform, PREFER protein refolding technology, and AI-based antigen remodeling. The company reports profitability from 2020 onward, with Q1 2025 molecular diagnostics revenue up 66.5% YoY and Q2 2025 revenue at 27 billion KRW (~$20M USD).
GeneMatrix firmographics
Firmographics- Name
- GeneMatrix
- Legal name
- Genematrix Inc.
- Website
- https://genematrix.net
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GeneMatrix is a South Korea-based molecular diagnostics company that develops and sells the NeoPlex™ line of proprietary multiplex real-time PCR kits, serving clinical laboratories and hospitals globally across infectious disease, HPV, STI, TB, and respiratory testing, while also advancing a six-candidate vaccine pipeline.
- Ownership category
- akta.pro rank
GeneMatrix industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where GeneMatrix is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
GeneMatrix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Molecular Diagnostic Kits Sales: GeneMatrix generates revenue through the sale of NeoPlex™ multiplex real-time PCR diagnostic kits for infectious disease detection. Products are sold in kit formats (96 tests/kit, 50 tests/kit) to clinical laboratories and healthcare facilities.
- Biochemical Diagnostic Reagents: Following acquisition of HBI in 2011, the company develops and sells general and special biochemical diagnostic reagents, expanding their product portfolio beyond molecular diagnostics.
- Vaccine Development: GeneMatrix is developing vaccines for hepatitis A, Japanese encephalitis, herpes zoster, COVID-19, Zika virus, and HPV therapeutic vaccine. Revenue from vaccines would come from commercialization upon regulatory approval.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | B2B quotation-based pricing for diagnostic kits |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
GeneMatrix product offering
Product offeringCore offering
GeneMatrix develops and manufactures multiplex real-time PCR diagnostic kits under the NeoPlex™ brand for simultaneous detection of multiple infectious disease pathogens including sexually transmitted infections, HPV, respiratory infections, tuberculosis, and gastrointestinal infections. The company also operates a biochemical diagnostics business under the HiSens™ brand acquired through HBI in 2011, and maintains a development pipeline of vaccine candidates using proprietary platform technologies.
Product overview
GeneMatrix is a molecular diagnostics and vaccine development company offering the NeoPlex™ line of multiplex real-time PCR diagnostic kits and a pipeline of 6 vaccine candidates. The NeoPlex™ product family includes respiratory infection panels (RV-Panel A for 10 viruses, RV-Panel B for 9 viruses, RB-8 for 8 bacteria, FluCOVID and COVID-19 FAST for SARS-CoV-2), TB/NTM-5 for tuberculosis detection, HPV detection kits (HPV29 for 29 types, HPV HR for 14 high-risk types), STI panels (STI-7, STI-7 PLUS, STI-14), and GI-Virus 6 for gastrointestinal pathogens. All NeoPlex™ products utilize the proprietary C-Tag™ single-tube multiplex PCR technology. The vaccine pipeline spans infectious diseases (Hepatitis A, Japanese encephalitis, Herpes zoster, COVID-19, Zika virus) and cancer (HPV therapeutic vaccine), developed using technology platforms including Chim-Ad™ vector, PREFER™ protein technology, and AI-based antigen remodeling.
Differentiator
Problem solved
Functional benefit
Brands
- NeoPlex: Multiplex real-time PCR diagnostic product line for molecular diagnostics including STI, HPV, respiratory infections, tuberculosis, and gastrointestinal infections
- HiSens
- Chim-Ad
- PREFER
Products and services
- NeoPlex™ STI-14 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 14 sexually transmitted infection-causing pathogens, designed for clinical laboratories performing molecular STI screening.
- NeoPlex™ STI-7 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 7 major STI-causing pathogens, targeted at clinical laboratories running routine molecular STI screening.
- NeoPlex™ STI-7 PLUS Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 7 additional STI-causing pathogens including Candida albicans and Gardnerella vaginalis, intended for laboratories needing expanded STI coverage including vaginitis-related organisms.
- NeoPlex™ HPV29 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection and genotyping of 29 HPV types (21 high-risk, 8 low-risk), used by clinical laboratories for cervical cancer screening and HPV surveillance.
- NeoPlex™ HPV HR Detection Single-tube multiplex real-time PCR assay for simultaneous detection and genotyping of 14 high-risk HPV genotypes, designed for clinical laboratories focused on high-risk HPV screening.
- NeoPlex™ RV-Panel A Detection Kit Single-tube multiplex real-time RT-PCR assay for simultaneous detection of 10 viral respiratory pathogens including Influenza A, Influenza A H1N1 pdm09, Influenza A H3N2, and RSV, intended for clinical laboratories and hospitals performing respiratory infection screening.
- NeoPlex™ RV-Panel B Detection Kit Single-tube multiplex real-time RT-PCR assay for simultaneous detection of 9 viral respiratory pathogens including Coronavirus OC43 and NL63, used by clinical labs running broader viral respiratory panels.
- NeoPlex™ RB-8 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 8 respiratory bacteria causing pneumonia, pertussis, and other infections, designed for clinical laboratories performing bacterial respiratory screening.
- NeoPlex™ FluCOVID Detection Kit One-step real-time RT-PCR assay for simultaneous detection of SARS-CoV-2, Influenza A and B viruses in a single test, designed for clinical laboratories and hospitals during respiratory virus season.
- NeoPlex™ COVID-19 FAST One-step real-time RT-PCR assay for fast detection of SARS-CoV-2 RdRp and N genes within 45 minutes using TaqMan technology, designed for rapid screening in clinical laboratories and point-of-need settings.
- NeoPlex™ COVID-19 Detection Kit One-step real-time RT-PCR assay for simultaneous detection of SARS-CoV-2 RdRp and N genes, supplied globally including to UNICEF during the COVID-19 pandemic for diagnostic use in clinical laboratories.
- NeoPlex™ TB/NTM-5 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of Mycobacterium tuberculosis and 5 pathogenic NTM species (M. abscessus, M. massiliense, M. avium, M. intracellulare, M. kansasii), intended for clinical laboratories performing mycobacterial screening.
- NeoPlex™ GI-Virus 6 Detection Kit Single-tube multiplex real-time RT-PCR assay for simultaneous detection of 6 gastrointestinal infection-causing pathogens including Norovirus GI and GII, used by clinical laboratories for gastroenteritis screening.
- HiSens™ Biochemical Diagnostic Reagents (Special Chemistry and General Chemistry) General and special biochemical clinical chemistry diagnostic reagents (marketed under the HiSens™ brand, including the HiSens™ Auto RPR LTIA syphilis screening test) sold to clinical laboratories and healthcare facilities for routine chemistry testing.
Quantifiable outcome
- 4X increase in experiment efficiency compared to single-plex testing
- +4 more outcomes
Companies that use GeneMatrix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
GeneMatrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature7 records
GeneMatrix partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- Jeonnam Bio Industry Promotion AgencyminorPartnership for hepatitis A vaccine efficacy evaluation and GMP production of COVID-19 vaccine candidate. Collaboration established through vaccine commercialization technology development project.
- Kyung Hee UniversityminorJoint development of domestically produced hepatitis A vaccine through infectious disease prevention and treatment technology development project awarded by Ministry of Health and Welfare.
- International Vaccine Institute (IVI)coreGeneMatrix collaborated with IVI, an internationally recognized organization, to conduct efficacy evaluation of COVID-19 vaccine candidate (GM-ChimAd-CV). IVI confirmed excellent cross-protection effects against mutant virus strains including delta variant.
- Korea Disease Control and Prevention AgencycoreJoint development of Zika virus recombinant vaccine candidate (GMZV-01) along with established vaccine purification and efficacy evaluation system.
- Vaccine Safety Technology Support CenterminorCollaborative partnership for hepatitis A vaccine efficacy evaluation methodology development as part of national vaccine development initiatives.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
GeneMatrix competitors and assessment
Company assessmentBroad incumbents
- Cepheid (Danaher): Global leader in molecular diagnostics with the GeneXpert system and Xpert multiplex test menu (respiratory, STI, HPV, MTB) — represents the dominant platform incumbent that GeneMatrix competes against in clinical lab settings.
- Hologic: Major molecular diagnostics player with the Panther system and Aptima assays for STI, HPV, and respiratory testing — broad incumbent competing with GeneMatrix in women's health and infectious disease molecular testing.
- Roche Diagnostics: Largest global diagnostics player offering cobas molecular systems and broad infectious disease test menus; competes with GeneMatrix for high-volume hospital and reference lab contracts worldwide.
- QIAGEN: Global molecular diagnostics and sample preparation technology provider with QIAstat-Dx multiplex syndromic panels (respiratory, GI) — directly comparable multiplex product offering to GeneMatrix's NeoPlex panels.
Direct peers
- Seegene: Seoul-based molecular diagnostics company specializing in multiplex real-time PCR technology with syndromic panels for respiratory, STI, HPV, and gastrointestinal infections — directly comparable to GeneMatrix's NeoPlex product line in technology and target markets.
- Osang Healthcare (OSANG Healthcare / GC Genome): Korean IVD manufacturer producing molecular diagnostic kits and rapid tests for infectious diseases including COVID-19, respiratory, and STI panels — overlapping with GeneMatrix's syndromic testing menu.
- SolGent: South Korean diagnostic company producing molecular diagnostic reagents and PCR-based kits for infectious diseases, including the DiaPlexQ multiplex product line — directly comparable to GeneMatrix's multiplex PCR positioning.
- Kogene Biotech: Korean molecular diagnostics company offering real-time PCR kits for infectious diseases including respiratory viruses, HPV, and sexually transmitted infections — overlapping product portfolio with GeneMatrix's NeoPlex line.
- Bioneer: Korean molecular diagnostics and life sciences company with PCR-based diagnostic kits and AccuPower product line, serving similar clinical laboratory customers as GeneMatrix in Korea and internationally.
Regional players
- Mestastem (in stem cell space): Listed on KOSDAQ with biotech focus; included as a regional Korean peer reference for comparable valuation dynamics rather than direct product competition, since specific multiplex PCR Korean small-cap peers beyond the named above are limited.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
GeneMatrix social profiles
Digital presenceGeneMatrix compliance and trust
Trust signalCompliance3 records
GeneMatrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneMatrix leadership team
Management profileNumber of profiles
Profiles2 records
GeneMatrix subsidiaries and ownership
Company hierarchySubsidiaries1 record
GeneMatrix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneMatrix M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneMatrix
What does GeneMatrix do?
GeneMatrix develops and manufactures multiplex real-time PCR diagnostic kits under the NeoPlex™ brand for simultaneous detection of multiple infectious disease pathogens including sexually transmitted infections, HPV, respiratory infections, tuberculosis, and gastrointestinal infections. The company also operates a biochemical diagnostics business under the HiSens™ brand acquired through HBI in 2011, and maintains a development pipeline of vaccine candidates using proprietary platform technologies.
Is GeneMatrix a public or private company?
GeneMatrix is a public company. It is classified as public and is currently operating.
When was GeneMatrix founded?
GeneMatrix was founded in 2000. It employs 51 to 100 people.
Where is GeneMatrix based?
GeneMatrix is headquartered in Seongnam, South Korea, in the Asia region.
How does GeneMatrix make money?
Three revenue lines are on record. Molecular Diagnostic Kits Sales are the primary driver. The others are biochemical Diagnostic Reagents and vaccine Development.
Who are GeneMatrix's main competitors?
Broad incumbents on record are Cepheid (Danaher), Hologic, Roche Diagnostics and QIAGEN. Direct peers are Seegene, Osang Healthcare (OSANG Healthcare / GC Genome), SolGent, Kogene Biotech and Bioneer. Mestastem (in stem cell space) is listed as a regional player.
Does GeneMatrix have an API?
No public API is recorded for GeneMatrix.
What industry is GeneMatrix in?
GeneMatrix's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.